New approaches to the medical treatment of irritable bowel syndrome

被引：2

作者：

Driss Berrada

Katia Canenguez

Tony Lembo

机构：

[1] Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215

来源：

Current Gastroenterology Reports | 2003年 / 5卷 / 4期

关键词：

Irritable Bowel Syndrome; Irritable Bowel Syndrome Patient; Loperamide; Tegaserod; Irritable Bowel Syndrome Symptom;

D O I：

10.1007/s11894-003-0072-0

中图分类号：

学科分类号：

摘要：

Irritable bowel syndrome (IBS) is a common disorder with a worldwide distribution; it is characterized by abdominal pain and discomfort associated with an alteration of bowel function. The treatment approach for IBS depends on the patient's presenting symptoms at the time of diagnosis, and treatment is usually directed toward the predominant symptom. In this review we discuss the current approach to the treatment of IBS. Copyright © 2003 by Current Science Inc.

引用

页码：337 / 342

页数：5

共 48 条

[21]

Novick J., Miner P., Krause R., Et al., A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation, Aliment. Pharmacol. Ther., 16, pp. 1877-1888, (2002)

[22]

Muller-Lissner S.A., Fumagalli I., Bardhan K.D., Et al., Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation, Aliment. Pharmacol. Ther., 15, pp. 1655-1666, (2001)

[23]

Whorwell P.J., Krumholz S., Muller-Lissner S., Et al., Tegaserod has a favorable safety and tolerability profile in patients with constipation-predominant and alternating forms of irritable bowel syndrome, Gastroenterology, 118, (2000)

[24]

Kellow J., Lee O., Chang F., Et al., An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome, Gut, 52, pp. 671-676, (2003)

[25]

Cann P.A., Read N.W., Holdsworth C.D., Barends D., Role of loperamide and placebo in management of irritable bowel syndrome (IBS), Dig. Dis. Sci., 29, pp. 239-247, (1984)

[26]

Hovdenak N., Loperamide treatment of the irritable bowel syndrome, Scand. J. Gastroenterol., 130, SUPPL., pp. 81-84, (1987)

[27]

Efskind P.S., Bernklev T., Vatn M.H., A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome, Scand. J. Gastroenterol., 31, pp. 463-468, (1996)

[28]

Callahan M.J., Irritable bowel syndrome neuropharmacology: A review of approved and investigational compounds, J. Clin. Gastroenterol., 35, SUPPL., (2002)

[29]

Lembo T., Wright R.A., Bagby B., Et al., Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol., 96, pp. 2662-2670, (2001)

[30]

Camilleri M., Northcutt A.R., Kong S., Et al., Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial, Lancet, 355, pp. 1035-1040, (2000)

← 1 2 3 4 5 →